solid end strong year guid call
solid fundament rais sale
project target price
erratum replac version publish jan correct jnj
devic growth figur cover page fig revenue fig
organ sale growth shi estim ep guid in-lin
manag close strong year solid quarter although organ growth
slightli cse consensu expect vs cse pharma
bright spot quarter estim recent intra-
quarter analysi continu see strength jnj pharma franchis pipelin
expect gener headwind eas vs manag remain engag
litig front expect stock perform improv declin uncertainti
regard rang potenti liabil face compani reiter outperform
rate rais target
ww devic growth organ us knee make comeback
deliv ww devic organ sale growth vs estim driven
part sequenti improv us knee roughli flat compar
improv us knee encourag result
next two week help determin whether improv reflect declin share
loss broad base market trend
ep cse consensu sale net cog
lower share lower tax partial off-set higher sg
non-op incom deliv ep upsid rel estim
penni consensu
sale guid expect ep guid lower due higher share
org sale growth guid ep guid reflect impact
higher share
valuat tp base ebitda multipl
ebitda bil previous bil new target multipl
roughli line jnj current trade multipl risk unexpect challeng pharma
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
charl martineau univers toronto impact litig regulatori qualiti issu
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
johnson johnson hold compani engag
 manufactur sale rang product health care
field oper compani organ busi segment
one-year valuat scenario base
ev/ebitda ebitda bil
scenario base high-growth segment grow
growth grow
one-year valuat grey scenario base
ev/ebitda grey ebitda bil
grey scenario base high-growth segment grow
growth grow
 close
pharmaceut bil mil y/i
immunolog sale driven strong uptak stelara crohn diseas
tremfya psoriasi partial off-set remicad due biosimilar gener
oncolog sale driven darzalex market growth share gain
 eu strong sale imbruvica partial off-set lower zytiga sale
lower velcad sale due gener competit
neurosci sale driven strength invega sustenna new
patient start partial off-set risperd consta
medic devic bil mil y/i
intervent solut sale oper driven electrophysiolog
growth continu double-digit atrial fibril procedur growth coupl
orthopaed oper driven hip sale trauma
knee partial off-set spine
surgeri sale strength advanc surgeri gener
surgeri partial off-set specialti surgeri
vision sale oper driven contact lenses/oth
partial off-set surgic
consum bil mil y/i
beauti sale driven dr ci labo acquisit along share gain
neutrogena aveeno partial off-set roc divestitur
over-the-counter sale driven primarili tylenol rapid releas gel arthriti pepcid
zarbe coupl overal market growth retail stock support
babi sale driven primarili due continu competit pressur
well comparison prior year relaunch activ notabl unit state
addit detail takeaway
pharmaceut bil mil y/i
immunolog sale bil mil oper growth
quarter driven strong double-digit perform stelara crohn diseas
tremfya psoriasi well strong market growth simponi aria remicad sale
declin due increas discounts/reb biosimilar competit
infecti diseas sale mil mil oper strong
sale symtuza juluca hiv partial off-set cannib increas gener
competit product
neurosci sale bil mil oper paliperidon
long-act inject grew due increas new patient start strong persist result
also driven continu launch spravato recent approv europ
oncolog sale bil mil oper darzalex
continu strong market perform grow roughli global imbruvica growth
driven larg market share gain strong market growth primarili chronic
lymphocyt leukemia indic along strong uptak ou lower sale
zytiga result gener competit partial off-set strong sale
share growth eu erleada growth driven launch uptak along share
gain non-metastat castration-resist prostat cancer avail twelv
emea countri erleada grew gain share quarter
pulmonari hypertens sale mil mil oper
growth quarter driven strong sale opsumit uptravi result
continu market growth share gain portfolio growth also impact declin
sale result continu gener competit
cardiovascular/metabolism/oth sale bil mil
oper declin primarili driven invokana biosimilar competit
procrit sale xarelto flat volum growth off-set rebat primarili due
higher donut hole util along higher medicar donut hole
salesy/i chg cc cg org cg salesy/i chg cc cg org metabolism/ charl martineau univers toronto januari
medic devic bil mil y/i
intervent solut sale mil mil oper
electrophysiolog grew continu double-digit growth trend consecut
year segment driven continu double-digit atrial fibril procedur growth
coupl strong diagnost cathet sale
orthopaed sale bil mil oper hip sale
mil mil oper growth driven jnj leadership
posit anterior approach continu strong demand primari stem acti
enabl technolog kincis surgic autom jointpoint
navig system knee sale mil mil oper
driven ou market growth new product strength china trauma sale
mil mil oper driven market growth support
strong adopt newer innov spine sale mil mil
oper driven base busi declin spine partial off-set growth
sport led new product monovisc robust double-digit aspac growth
ortho price pressur continu impact categori orthopaed compar
pure price spine declin adjust last year pricing-rel true-up
trauma price consist declin hip knee
improv compar neg flat vs respect
surgeri sale bil mil oper advanc
surgeri sale driven endocutt led
ou growth driven share gain new product aspac region partial off-set
competit pressur unit state biosurgeri driven growth
region led aspac gener surgeri growth led wound closur growth
driven strong perform aspac due market share growth china well
market growth share gain convent barb sutur specialti
surgeri growth led asp divestitur
vision sale bil mil oper contact
lenses/oth sale mil mil oper growth
led daili dispos asi surgic sale mil mil
driven strong ou growth cataract busi due above-market perform
iol primarili aspac partial off-set weak perform due competit
pressur lower market growth refract surgeri
salesy/i chg cc cg org cg salesy/i chg cc cg org cg medic charl martineau univers toronto januari
consum bil mil y/i
babi sale mil mil oper declin
primarili due continu competit pressur well comparison prior year
relaunch activ notabl unit state
beauti sale bil mil oper growth driven
dr ci labo acquisit along share gain neutrogena aveeno partial off-set
oral sale mil mil oper growth
primarili driven increas trade invest partial off-set success
promot strong consumpt emea
over-the-counter sale bil mil oper growth attribut
grow share multipl product adult tylenol driven rapid-releas gel
pepcid zarbe
women sale mil mil oper
growth segment driven stayfre perform india
wound care/oth sale mil mil oper primarili
due market growth adhes bandag
salesy/i chg cc cg org cg salesy/i chg cc cg org estimate varianc charl martineau univers toronto januari
 oper margin bp
sale net cog lower share lower tax partial
off-set higher sg non-op incom deliv ep upsid rel
estim penni consensu effect tax rate quarter
consist includ estim tax expens transit
provis swiss tax reform partial off-set reorgan certain foreign subsidiari
addit impact recent issu regul associ tax reform
manag issu organ sale growth guidanc equat
bil revenu guidanc organ growth includ bp benefit addit
ship day associ fiscal week last time partial off-set
bp consum sku ration program context compani expect
ration sku across ww consum portfolio expect
translat neg impact top line growth slightli bp program
primarili focus ou larger impact come babi beauti
franchis expect neg impact sell day medic
devic segment bp major off-set
expect biggest benefit addit sell day ep guid
rang
estimate bpop bpnon-op bpnet chg y/i charl martineau univers toronto januari
chang model
increas sale estim decreas ep estim
reflect new guidanc also made rel minor adjust top-lin
project beyond increas sale estim per year averag
decreas year ep estim
figur chang model
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
